Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of QCC374 in Healthy Subjects
NCT02245828Phase 1Completed
- Sponsor
- Novartis
- Start
- Jul 2014
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing QCC374 with Placebo (2 arms). Primary endpoint: Safety and tolerability at 39 days. Started Jul 2014; status: completed.
02
Drugs
QCC374
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02245828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02245828.